Related Experiment Video
Updated: Mar 29, 2026

Author Spotlight: Investigating Islet Abnormalities and Function with a Pseudoislet Protocol
Published on: November 3, 2023
Artificial Pancreas Device Systems for the Closed-Loop Control of Type 1 Diabetes: What Systems Are in Development?
Sara Trevitt1, Sue Simpson2, Annette Wood2
1NIHR Horizon Scanning Research & Intelligence Centre, University of Birmingham, Birmingham, UK s.trevitt@bham.ac.uk.
Eighteen artificial pancreas device (APD) systems are in development for type 1 diabetes management. Most are in early trials, with a few nearing commercialization, offering automated blood glucose control.
Area of Science:
- Medical Devices
- Biomedical Engineering
- Endocrinology
Background:
- Artificial pancreas device (APD) systems are emerging external medical devices for automated blood glucose regulation in type 1 diabetes.
- These systems leverage digital communication and advanced algorithms for hands-free, continuous glycemic control.
Purpose of the Study:
- To conduct a horizon scanning review of developing closed-loop artificial pancreas device systems.
- To classify identified systems based on automation, control strategies, and research settings.
Main Methods:
- Horizon scanning review utilizing online intelligence sources.
- Classification of systems by automation level, hormonal/glycemic control methods, and research environment (inpatient, outpatient, home).
Main Results:
- Eighteen closed-loop APD systems were identified in clinical trials.
- Systems are being tested in various settings: 6 in home, 5 outpatient, 7 inpatient.
- Commercial availability estimated for 5 systems in the EU between late 2016 and 2018.
Conclusions:
- Approximately 18 closed-loop APD systems are in early clinical development.
- Few systems have advanced to phase 3 trials in real-life settings.
- Further development and trials are needed for widespread adoption.
Related Concept Videos
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Insulin: Biosynthesis, Chemistry, and Preparation
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
Insulin and C-peptide are...
Carbohydrate Metabolism
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

